China's Jinxin Fertility Group interim revenue rises on U.S. IVF demand

Jinxin Fertility

21/08/2026 11:23

Overview
China fertility clinic operator's interim revenue for six months to June 30 grew 6.6% yr/yr
Net profit for the six months turned positive, compared to a loss in prior year
Company board does not recommend interim dividend for the period

Outlook
Jinxin Fertility targets 2026-28 annual shareholder returns of 50%-80% of non-IFRS adjusted EBITDA

Result Drivers
U.S. IVF DEMAND – Revenue benefited from California SB 729 implementation and physician recruitment, lifting U.S. revenue by RMB 87.1 mln
 PRIOR-YEAR IMPAIRMENTS – Net profit swung to RMB 110.3 mln as H1 2025 included RMB 992.6 mln of goodwill and intangible-asset impairments
MARKETING INVESTMENT – Selling and distribution expenses rose 23.9% yr/yr, reflecting brand-building and Greater Bay Area headquarters promotion

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 1.37 bln
 
H1 Net Income Attributable
 
RMB 107.40 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Jinxin Fertility Group Limited is HK$3.06, about 37.2% above its August 21 closing price of HK$2.23
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 21 three months ago

Reuters Recommended Reads
Aug 20 - China's Simcere Pharmaceutical H1 revenue rises on neuroscience, autoimmune drugs strength
Aug 20 - China's top drugmaker Hengrui sees profit growth squeezed by bulk-buying programs
Aug 20 - Chinese medical device maker Zylox-Tonbridge's revenue rises 31%, aided by global expansion

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)